• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>NPS Pharmaceuticals

NPS Pharmaceuticals

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Shire Reports Topline Results from First of Three Placebo-Controlled Phase 2 Studies of SHP625 (LUM001) in Children with Alagille Syndrome

    Shire Reports Topline Results from First of Three Placebo-Controlled Phase 2 Studies of SHP625 (LUM001) in Children with Alagille Syndrome

  2. Shire Announces Clear Regulatory Path Forward for SHP465, an Investigational Treatment for Adults with ADHD

    Shire Announces Clear Regulatory Path Forward for SHP465, an Investigational Treatment for Adults with ADHD

  3. Five Things You Should Know About U.S. Small-Caps

    NPS Pharmaceuticals NPSP raised $50 million Monday through the sale of its Preotact royalty stream to Drug Royalty Corporation. We're maintaining our fair value estimate as we believe the exchange was fair but not favorable to shareholders. The proceeds will satisfy part of a $190 million ...

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.